# reload+after+2024-01-22 08:43:17.876041
address1§285 Summer Street
address2§Suite 101
city§Boston
state§MA
zip§02210
country§United States
phone§617 995 0900
fax§617 995 2410
website§https://www.aileronrx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§6
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Manuel C. Aivado M.D., Ph.D.', 'age': 53, 'title': 'President, CEO & Director', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 700570, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. D. Allen Annis Ph.D.', 'age': 50, 'title': 'Senior Vice President of Research', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 422014, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Susan L. Drexler CPA, M.B.A.', 'age': 53, 'title': 'Interim CFO, Principal Financial Officer & Principal Accounting Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.274
currency§USD
dateShortInterest§1702598400
forwardEps§-0.8
pegRatio§-0.76
exchange§NCM
quoteType§EQUITY
shortName§Aileron Therapeutics, Inc.
longName§Aileron Therapeutics, Inc.
firstTradeDateEpochUtc§1498743000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§aab0072b-67d5-3152-ae06-7c7794bcf03f
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§9.0
targetMeanPrice§9.0
targetMedianPrice§9.0
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§7.432
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
